anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The means and the method are used in dentistry for the prophylaxy and treatment of initial forms of dental caries. The means contains water soluble calcium and phosphate salts having constant ion activity in suitable gel form which is indifferent and does not affect the oral cavity mucous membrane and teeth and does not stimulate the development of dental scale. By the method, lasting and more stable penetration of the phosphate-calcium ions and filling of the enamel cracks is achieved. By it, a two-stage gel system is used consisting of phosphate anionic gel and calcium cationic gel which are applied successively in such a manner that calcium phosphates participating in the remineralization of the enamel precipitate on the dental surface. The gels contain from 5 to 15% methylcellulose. Water soluble phosphate salts are contained in the phosphate anionic gel in concentrations, in %: from 0.4 to 10 collagen; 0.2-1 biologically active substance; 0.01 to 1 fluoride additives, and other microelements up to 0.2. The cationic gel contains in %: from 0.5 to 12 calcium soluble salts, 0.1-1 collagen, 0.01-1 biologically active substances and 0.01-2 microelements.
The present invention relates to methods for disinfecting or decontaminating a material or for preventing an infection or contamination of a material. The invention further relates to compositions which are suitable for disinfecting a material or for preventing an infection or contamination of a material and to uses of such compositions. The invention further relates to a medical use of chitosan and to a pharmaceutical composition comprising the chitosan. The invention further relates to a method of treating a microbial infection and to an aqueous solution comprising chitosan. The invention moreover relates to a chitosan or a pharmaceutical composition comprising a chitosan for an epithelial cell growth stimulating treatment of a patient's tissue and to a method of stimulating the growth of epithelial cells. The invention also relates to a tissue dressing material.
### Amoxicillin/lansoprazole

Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1 year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Indicated surgical procedures should be performed.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor manifesting strong inhibiting activities against an enzyme for forming dental plaque by a trace amount and having high safety by using an extract of leaf, bark and/or core of a specific tree belonging to the genus Betula of the family Betulaceae with water or an organic polar solvent as an active ingredient. SOLUTION: The objective inhibitor is obtained by using an extract obtained by carrying out an extraction treatment (e.g. a heating and refluxing method or a dipping method) of leaf, bark and/or core of at least one kind of a tree [preferably Betula platyphylla Sukatchev var. japonica (Miq.) Hara] selected from Betula platyphylla Sukatchev var. japonica (Miq.) Hara, Betula papyrifera Marsh, Betula maximowicziana Regel, Betula scmidtii, Betula szechuanica Schneid, Betula pendula Roth, Betula ermanii Cham. var. ermanii, Betula populifolia, Betula davurica Pallas, Betula tatewakiana, Betula pendula and Betula pubescens with water or an organic polar solvent (preferably water, ethanol or a mixture thereof) as an active ingredient.
PROBLEM TO BE SOLVED: To obtain a cleaning agent composition which maintains a good cleaning force, is mild for the skins, and gives excellent touch to the skins, when and after the skins are cleaned, by making the composition contain the power of a crude drug to a powdery or granular cleaning agent. SOLUTION: This cleaning agent composition contains a powdery or granular cleaning agent and further the powder of a crude drug (preferably one or more galenicals selected from among Gardeniac Fructus, Phellodendri cortex, Plantago seed, Purataria lobata, Crataegus cuneata, Pachyma hoelen, Cyperus rhizome, Alisma rhizome, coix seed, Japanese apricot seed, peach kernel, angericae radix, Cnidii Rhizome, citrus unshiu peel, Angelica dahurical Root, Atractylodes rhizome, Atractylodes lancea rhizome, schisandra fruit and jujube seed). The crude drug power is preferably added in an amount of 0.05-5 wt.% based on the composition. The cleaning agent component and crude drug powder preferably have an average particle diameter ratio of 1:10 to 10:1. The average particle diameter of the galenical powder is preferably 20-2,000 μm.  The cleaning agent composition may be compounded with a surfactant, an emollient agent, an antiseptic, etc., in addition to the crude drug.
A centrally controlled healthcare environment interconnects manufacturers of medical products, healthcare providers, and patients in a manner that provides a variety of functionalities. A particularly advantageous application of the system provides a mechanism for regulating and recording the flow of free drug samples from manufacturers to healthcare providers and thence to patients. This involves a method by which a unique record is created each time it changes hands on the way from the manufacturer to the patient. A machine-readable unique code assigned to the sample is scanned automatically when the sample it is withdrawn from inventory at the manufacturer. The code and a unique identity of the individual withdrawing the sample are stored as a first record. This process is repeated at each location and for each individual handling the sample, including when it reaches the healthcare provider. Thus, a series of unique records is created that track the sample.
Physicians should consider reminding the patient of the following: To take each dose with meals and with a full glass of water or other liquid. To take each dose without crushing, chewing, or sucking the tablets. If those patients are having difficulty swallowing whole tablets, they may try one of the following alternate methods of administration:

  1. Break the tablet in half, and take each half separately with a glass of water. 
  2. Prepare an aqueous (water) suspension as follows:   
1\. Place the whole tablet(s) in approximately 1/2 glass of water (4 fluid ounces).   
2\. Allow approximately 2 minutes for the tablet(s) to disintegrate.   
3\. Stir for about half a minute after the tablet(s) has disintegrated.   
4\. Swirl the suspension and consume the entire contents of the glass immediately by drinking or by the use of a straw.   
5\. Add another 1 fluid ounce of water, swirl, and consume immediately.   
6\. Then, add an additional 1 fluid ounce of water, swirl, and consume immediately. 



Aqueous suspension of Potassium Chloride that is not taken immediately should be discarded. The use of other liquids for suspending Potassium Chloride Extended Release Tablets USP, 20 mEq is not recommended.

To take this medicine following the frequency and amount prescribed by the physician. This is especially important if the patient is also taking diuretics and/or digitalis preparations.

To check with the physician at once if tarry stools or other evidence of gastrointestinal bleeding is noticed.
Recent evidence has shown that a multimodal rehabilitation program can accelerate recovery of GI function after colon resection. 8 A multicenter, randomized, placebo-controlled, double-blind, phase 3 trial demonstrated that Alvimopan, a peripherally acting mu-opioid receptor antagonist, appears to accelerate GI tract recovery by 1 day, and reduces postoperative ileus-related morbidity without compromising opioid analgesia. 9 Asao et al demonstrated that gum chewing can accelerate recovery of GI function, also by 1 day, after abdominal surgery. 10 Epidural anesthesia has been shown to shorten duration of POI, as well as improve pain control, decrease pulmonary complications, and quicken recovery times. However, it does not appear to reduce overall length of stay. 4 However, Neudecker et al. were unable to reproduce the results of previous trials evaluating the effect of thoracic epidural analgesia on duration of postoperative ileus following laparoscopic sigmoid resection. 11 Given conflicting data, no one single measure has been adopted for the prevention POI.

Recent evidence has shown that coffee may be a stimulant for the GI Tract. A small study of 16 healthy volunteers demonstrated that coffee appears to increase rectal tone thus implying an impact on defecation mechanics.12 Furthermore, several studies have demonstrated caffeinated coffee to be a stimulant of motor activity in the colon.13,14 Given its potential pro-motility properties in the GI tract, it seems reasonable to postulate that coffee, a commonly consumed product by the general public, may play a role in shortening and possibly preventing POI. This directly impacts overall patient satisfaction but will reduce length of stay and overall hospital costs.
A comprehensive database system employs common medical terms, vocabularies and identifiers in identifying organizational characteristics as well as location availability and suitability for delivering services by a particular physician to a patient with particular medical conditions via a user friendly display interface. A system for managing healthcare data including codes, terms and identifiers supports operation of a healthcare enterprise. The system includes a first database including healthcare data including elements common to a plurality of healthcare organizations and derived from a plurality of different sources. The healthcare data common elements support use of consistent terminology between the plurality of organizations. A processor provides at least a portion of the healthcare data in the first database to a second database employed by at least one of the plurality of organizations in response to user command. The second database also supports use of user selectable items of healthcare data. An interface processor intermittently receives healthcare data updates for incorporation in the first database.
Requesting assistance for a medical event occurring in a hospital comprises receiving data regarding the location of the medical event, receiving data regarding a type of the medical event and receiving data regarding at least one wirelessly detectable tag. Each wirelessly detectable tag is associated with a respective clinician. A location of each clinician within the hospital is determined based at least in part on the data regarding the at least one wirelessly detectable tag, which may be an identifier related to a clinician profile. At least one particular clinician is identified as being eligible to provide assistance, based at least in part on the location of the medical event, the type of the medical event, and the respective location of each clinician. Assistance for the medical event is requested from each particular clinician, by means of paging, email or phone. In the event of non-response by the particular clinician, a surrogate clinician may be identified.
Participants will consume 100 g Miso fermented tofu per day which may be consumed any way i.e. fried, grilled, baked, etc to taste or prepared from the list of recipes provided.
A high-precision system was developed for the quantification of biological analytes in single cells (reactive oxygen species (ROS) and reactive nitrogen species (RNS)) based on the electrochemical amperometric method. The efficacy of this system was evaluated using an experimental bacteremia model. Endothelial cells exhibited increased ROS/RNS production when stimulated by Staphylococcus aureus. However, they remained inactive when exposed to either unprimed or primed neutrophils that had been pre-incubated with bacteria. It is noteworthy that the sequential stimulation of endothelial cells with bacteria followed by neutrophils resulted in a significant increase in the ROS/RNS level, which demonstrated a correlation with the number of neutrophils in contact with the endothelial cells. These results highlight the potential of our system to quantitatively assess ROS/RNS dynamics in complex biological systems. They also offer insights into the interplay between various cellular components in experimental bacteremia.
PROBLEM TO BE SOLVED: To provide a coating device capable of smoothly discharging, out of a rotary drum, granules in the interior of the rotary drum via a discharge member such as a discharge plate, etc., of performing a safe and efficient checkup operation, etc., and of inhibiting, in a case where a treatment gas is fed into the rotary drum interior via a mouth ring unit from an aperture unit on one terminal side, the turbulence of the flow of the treatment gas by the rotation of the discharge member.SOLUTION: The anterior terminal portion of a rotary drum 1 is constituted by a cyclic mouth ring unit 1d. An anterior terminal aperture unit 1e is configured on the anterior terminal of the mouth ring unit 1d. The inner circumferential surface 1d1 of the mouth ring unit 1d is formed as a conical surface having a progressively expanding diameter toward the forward side. A discharge plate is configured in the interior of the rotary drum 1. Granules in the interior of the rotary drum 1 are guided to the mouth ring unit 1d by the discharge plate based on the rotation of the rotary drum. The granules guided to the mouth ring unit 1d, furthermore, are discharged out of the rotary drum 1 via the anterior terminal aperture unit 1e after having been guided by the inner circumferential surface 1d1 of the mouth ring unit 1d.
Participants will receive two doses of Dose Level 1 each, using one of the following two sequences: (i) AI on Day 1 of Treatment Period 1, followed by vial on Day 1 of Treatment Period 2; or (ii) vial on Day 1 of Treatment Period 1, followed by AI on Day 1 of Treatment Period 2. A washout period of 28-42 days will be maintained between the 2 treatment periods.
Participants will receive JNJ-67896049 tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
Up to 30 women that will be referred for colposcopy examination at the standard indications will also undergo a colposcopy examination of the cervix by a gynescope. The physicain performing the optical test will record the findings in accordance with the International Federation for Cervical Pathology and Colposcopy (IFCPC) terminology. Categorical variable will be included in every record. At later stage, the images obtained by the cervicography will be evaluated and recorded in accordance with the IFCPC terminology. Correlation between the categorical findings in both assesments will be compared. The correlation measure will be performed by Kappa test according to the categorial result of both measurements.
BACKGROUND: Chromosome 7 has regions enriched with low copy repeats (LCRs), which increase the likelihood of chromosomal microdeletion disorders. Documented microdeletion disorders on chromosome 7 include both well-known Williams syndrome and more rare cases. It is noteworthy that most cases of various microdeletions are characterized by phenotypic signs of neuropsychological developmental disorders, which, however, have a different genetic origin. The localization of the microdeletions, the genes included in the region, as well as the structural features of the sequences of these genes have a cumulative influence on the phenotypic characteristics of the individuals for each specific case and the severity of the manifestations of disorders. The consideration of these features and their detailed analysis is important for a correct and comprehensive assessment of the disease.
RESULTS: The article describes a clinical case of 7p22.3 microdeletion in a patient with congenital heart defect and neurological abnormalities - epilepsy, combined with moderate mental and motor developmental delay.
CONCLUSIONS: Through detailed genetic analyses, we are improving the clinical description of the rare 7p22.3 microdeletion and thus creating a basis for future genetic counseling and research into targeted therapies.
PURPOSE: A cosmetic composition containing an extract of Punica granatum L. having excellent antioxidant effect is provided. The cosmetic composition containing the extract has excellent skin elasticity-improving effect and antioxidant effect as well as a synthetic effect of a collagen fiber. Therefore, it has excellent preventing and improving effect on aging. CONSTITUTION: A cosmetic composition contains 0.01 to 10% by weight of an extract of Punica granatum L., based on the total weight of the composition. The extract is obtained by extracting the skin, fresh and seed powder of Punica granatum L. in one or more solvents selected from the group consisting of water, ethanol, methanol, acetone, glycerin, squalane and 1,3-butylene glycol, filtration, concentration under reduced pressure and spray drying. The Punica granatum L. extract is fermented at 20 to 25deg.C for 6 to 8 days with yeast, filtered and aged for 29 to 31 days to be added to a cosmetic.
Patients who had gone through bowel resection due to obstruction. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
Biomedical and biotechnology industry is internationally regarded as the most brilliant star performer of the future. The development of biomedical depends on a high quality academic research environment, while innovation and uniqueness should be emphasized for the development of biotechnology industry. The successful development of biotechnology industry will be impossible if the development is not based on extensive and in-depth research work and verification acquired from clinical implementation. Based on these concepts, the resources of research materials, especial of human being, are going to be essential. Thus, a programmable and systematic collection of clinical specimen would become one of the potential properties in hospital. This is a two-year pilot scheme, and was designed to start collecting specimen from "Health Management Center" in NTUH. This pilot scheme will address important issues of manpower, finances, and data merging for evaluation of biotechnological related specimen collection, such as cell or tissue bank, in the future.

There are 12471 persons who take the health examination in Health Management Center during 2004 Mar -2005 Dec. Subjects agree to be invovled in the study asre assigned as "respondent". For those who disgree to be involved in the study are assigned as "non-respondent". There are 6261 respondents and 6210 non-respondents in this study. 63% of respondents and 51% of non-respondents are males. There is a lower distribution in smoking, history of hypertension, and history of hyperlipidemia in respondents than in non-respondents. Respondents have lower level of triglyceride, HDL, LDL in blood than non-respondents do.
Since the introduction of Xalatan generic versions of latanoprost have entered the Canadian marketplace such as Apo-latanoprost (Apotex Inc.), Co-latanoprost (Cobalt Pharmaceuticals Co.) and Sandoz latanoprost (Sandoz Canada Inc.). The exact formulation of the different preparations of latanoprost may differ between manufacturers, although the active ingredient itself is not supposed to vary within a 15% tolerance. In a topical ocular medication in a multi-dose dispenser, the stability of the drug and its ability to penetrate the cornea into the eye may affect the efficacy of the drug.

There are no clinical trials to compare the efficacy of generic versions of latanoprost to Xalatan, nor are there any clinical trials comparing efficacy between the different generic versions. Empirical evidence based on clinical experience suggests that at least some of the generic versions of latanoprost may not be as effective as the branded version (Xalatan). Intraocular pressure is often observed to increase when switching from a branded to generic version of latanoprost, but the opposite is rarely if ever observed. The purpose of this study will be to compare the efficacy of Xalatan to two of the most popular generic versions of latanoprost available in Canada (Apo-latanoprost and Co-latanoprost).
INTRODUCTION: Increased BMI has been identified as a risk factor for most pregnancy complications, but the underlying metabolic factors mediating the detrimental effects of BMI are largely unknown. We aimed to compare metabolic profiles in overweight/obese women (body mass index [BMI] ≥ 25 kg/m2 ) and normal weight/underweight women (BMI < 25 kg/m2 ) across gestation. We also explored how gestational weight gain (GWG) affected maternal metabolic profiles.
MATERIAL AND METHODS: Exploratory nested case-control study based on a prospective longitudinal cohort of women who were healthy prior to pregnancy and gave birth at Oslo University Hospital from 2002 to 2008. The sample consisted of 48 women who were overweight/obese and 59 normal-weight/underweight women. Plasma samples from four time points in pregnancy (weeks 14-16, 22-24, 30-32 and 36-38) were analyzed by nuclear magnetic resonance spectroscopy and 91 metabolites were measured. Linear regression models were fitted for each of the metabolites at each time point.
RESULTS: Overweight or obese women had higher levels of lipids in very-low-density lipoprotein (VLDL), total triglycerides, triglycerides in VLDL, total fatty acids, monounsaturated fatty acids, saturated fatty acids, leucine, valine, and total branched-chain amino acids in pregnancy weeks 14-16 compared to underweight and normal-weight women. Docosahexaenoic acid and degree of unsaturation were significantly lower in overweight/obese women in pregnancy weeks 36-38. In addition, overweight or obese women had higher particle concentration of XXL-VLDL and glycoprotein acetyls (GlycA) at weeks 14-16 and 30-32. GWG did not seem to affect the metabolic profile, regardless of BMI group when BMI was treated as a dichotomous variable, ≥25 kg/m2 (yes/no).
CONCLUSIONS: Overweight or obese women had smaller pregnancy-related metabolic alterations than normal-weight/underweight women. There was a trend toward higher triglyceride and VLDL particle concentration in overweight/obese women. As this was a hypothesis-generating study, the similarities with late-onset pre-eclampsia warrant further investigation. The unfavorable development of fatty acid composition in overweight/obese women, with possible implication for the offspring, should also be studied further in the future.